Celltrion Keeps Pace With Ustekinumab Discounts As It Launches US Stelara Rival
Steqeyma Version Introduced With WAC 85% Lower Than $10bn Brand
Celltrion has become the latest firm to enter the competitive US market for Stelara biosimilars, revealing details of its Steqeyma launch.
